US-based AI biotechnology company Dewpoint Therapeutics and Germany-based drug discovery company Evotec have collaborated to advance Dewpoint's oncology programs by leveraging Evotec's INDiGO technological platform. The terms and financial details of the agreement have not been disclosed.

The partnership will leverage Dewpoint's oncology pipeline programs, identified using condensate biology and AI technology alongside Evotec's leading experience in speeding up and de-risking pre-clinical development candidates. 

Evotec's INDiGO platform will help fast-track Dewpoint's oncology treatments toward Investigational New Drug Applications (INDs). The agreement incorporates a risk-sharing arrangement, followed by milestone and royalty payments to Evotec based on the success of the partnership.